These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma. Liu X; Chen L; Zhang T Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532 [TBL] [Abstract][Full Text] [Related]
70. PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression. Lee YF; Phua CZJ; Yuan J; Zhang B; Lee MY; Kannan S; Chiu YHJ; Koh CWQ; Yap CK; Lim EKH; Chen J; Lim Y; Lee JJH; Skanderup AJ; Wang Z; Zhai W; Tan NS; Verma CS; Tay Y; Tan DSW; Tam WL Genome Med; 2024 Jul; 16(1):91. PubMed ID: 39034402 [TBL] [Abstract][Full Text] [Related]
71. The upregulation of TMPRSS4, partly ascribed to the downregulation of miR‑125a‑5p, promotes the growth of human lung adenocarcinoma via the NF‑κB signaling pathway. Fan X; Liang Y; Liu Y; Bai Y; Yang C; Xu S Int J Oncol; 2018 Jul; 53(1):148-158. PubMed ID: 29750426 [TBL] [Abstract][Full Text] [Related]
72. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642 [TBL] [Abstract][Full Text] [Related]
73. RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53. Jung JH; Lee H; Cao B; Liao P; Zeng SX; Lu H Oncogene; 2020 Jan; 39(5):1031-1040. PubMed ID: 31591476 [TBL] [Abstract][Full Text] [Related]
74. Comprehensive analysis of lncRNA expression profiles and identification of functional lncRNAs in lung adenocarcinoma. Qiu M; Feng D; Zhang H; Xia W; Xu Y; Wang J; Dong G; Zhang Y; Yin R; Xu L Oncotarget; 2016 Mar; 7(13):16012-22. PubMed ID: 26918601 [TBL] [Abstract][Full Text] [Related]
75. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022 [TBL] [Abstract][Full Text] [Related]
76. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data. Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415 [TBL] [Abstract][Full Text] [Related]
77. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Liu HX; Cartegni L; Zhang MQ; Krainer AR Nat Genet; 2001 Jan; 27(1):55-8. PubMed ID: 11137998 [TBL] [Abstract][Full Text] [Related]
78. A Novel Long Non-Coding RNA, SOX21-AS1, Indicates a Poor Prognosis and Promotes Lung Adenocarcinoma Proliferation. Lu X; Huang C; He X; Liu X; Ji J; Zhang E; Wang W; Guo R Cell Physiol Biochem; 2017; 42(5):1857-1869. PubMed ID: 28873379 [TBL] [Abstract][Full Text] [Related]
79. Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma. Wang Y; Wang G; Zheng H; Liu J; Ma G; Huang G; Song Q; Du J Front Oncol; 2022; 12():1014997. PubMed ID: 36531058 [TBL] [Abstract][Full Text] [Related]